NASDAQ$TERN
Terns Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Terns Pharmaceuticals reported third quarter 2021 financial results.
Terns Pharmaceuticals reported a net loss of $11.8 million for the third quarter ended September 30, 2021. The company's cash and equivalents were $177.2 million as of September 30, 2021, providing a cash runway into 2024.
- Top-line data from TERN-201 (VAP-1) clinical trial in NASH is expected in 1Q 2022.
- Positive top-line data from TERN-501 (THR-β) demonstrated clinical proof of concept, enabling the planned initiation of NASH trial in 1H 2022.
- Multiple abstracts detailing positive clinical data for TERN-101 and TERN-501 were presented at AASLD 2021.
- Cash and equivalents of $177 million provides runway into 2024.
Headline financials
Revenue & EPS history
Terns · Revenue · Quarterly
$0
Forward guidance
Terns Pharmaceuticals anticipates top-line data from the AVIATION Trial of TERN-201 in the first quarter of 2022 and plans to initiate a clinical trial in NASH patients including both monotherapy and combination arms of TERN-101 and TERN-501 in the first half of 2022.
Tailwinds
- TERN-201: Top-line data from AVIATION Part 1 expected in 1Q 2022, including key efficacy readout in corrected T1 (cT1) levels.
- TERN-501: Data support plans to initiate in 1H 2022 Terns’ first NASH trial of a THR-β agonist (TERN-501) alone and in combination with a farnesoid X receptor (FXR) agonist (TERN-101).
- TERN-101: cT1 declined significantly as early as Week 6 with persistent decreases through Week 12 in all TERN-101 groups compared to placebo, with cT1 changes at Week 6 strongly correlated with changes at Week 12
- Development candidate anticipated to be designated as TERN-601 in 4Q 2021
- Cash position supports planned operating expenses into 2024
Headwinds
- The impact of the COVID-19 pandemic on the Company’s ability to progress with its research, development, manufacturing and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time.
- The company's clinical trials and research and development activities are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially.
- The Company’s ability to progress with its research, development, manufacturing and regulatory efforts depends on the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries.
- The Company’s ability to execute on its clinical strategy and plans is subject to the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials.
- The Company's expectations of timing and potential results of the Company’s clinical trials and other development activities are forward-looking statements that are subject to risks and uncertainties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+16.4%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+19.8%
Q4 2022
Best reaction
-23.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.3% | -0.0% | — | |
| Q3 2025 | +7.6% | +18.0% | +146.3% | |
| Q2 2025 | -6.8% | +3.6% | +18.7% | |
| Q1 2025 | -0.7% | -4.1% | +22.3% | |
| Q4 2024 | -2.7% | -1.3% | -23.6% | |
| Q3 2024 | -9.1% | -17.3% | -11.7% | |
| Q2 2024 | -4.6% | -11.8% | -1.7% | |
| Q1 2024 | +7.7% | +6.1% | +32.9% | |
| Q4 2023 | +1.7% | -15.0% | -27.4% | |
| Q3 2023 | +14.2% | +10.1% | +92.3% | |
| Q2 2023 | -9.5% | +0.8% | -21.5% | |
| Q1 2023 | -15.2% | -20.3% | -7.0% | |
| Q4 2022 | +19.8% | +32.7% | +42.3% | |
| Q3 2022 | -23.0% | -26.7% | -12.2% | |
| Q2 2022 | -5.5% | +39.2% | +75.1% | |
| Q1 2022 | +4.0% | -0.7% | +26.5% | |
| Q4 2021 | +4.1% | +3.5% | -5.4% | |
| Q3 2021 | -1.2% | -5.9% | -30.9% | |
| Q2 2021 | +4.3% | +3.5% | -0.9% | |
| Q1 2021 | +3.6% | +5.6% | +13.5% | |
| Q4 2020 | +5.8% | -0.9% | +1.2% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro